Fig 4.

Expression of glomerular fibronectin and TGF-β are not reduced with loss of CnAβ (A) Fibronectin expression in control and diabetic wild-type (i, ii) and β^−/−mice (iii, iv) was determined by immunofluorescence using Cy3-con-jugated secondary antibody to detect antifibronectin antibodies. (B) Results from four to six mice per group were then semi-quantitated and graphed. *P< 0.05, two-way anova. (C) TGF-β expression in control and diabetic wild-type (i, ii) and CnAβ^−/− mice (iii, iv) was determined by immunofluorescence using fluoroscein isothiocyanate (FITC)-conjugated secondary antibody to detect anti- TGF-β antibodies. (D) Results from four to six mice per group were then semi-quantitated and graphed. *P < 0.05, **P < 0.01 compared to control; #P< 0.05 compared to wild-type, two-way anova with Bonferroni's post-test.